TY - JOUR
T1 - Paravalvular aortic regurgitation severity assessed by quantitative aortography
T2 - Acurate neo2 versus acurate neo transcatheter aortic valve implantation
AU - Rück, Andreas
AU - Kim, Won-Keun
AU - Kawashima, Hideyuki
AU - Abdelshafy, Mahmoud
AU - Elkoumy, Ahmed
AU - Elzomor, Hesham
AU - Wang, Rutao
AU - Meduri, Christopher U.
AU - Verouhis, Dinos
AU - Saleh, Nawzad
AU - Onuma, Yoshinobu
AU - Mylotte, Darren
AU - Serruys, Patrick W.
AU - Soliman, Osama
N1 - Funding Information:
Conflicts of Interest: Andreas Rück reports grants from Boston Scientific during the conduct of the study, and reports grants, personal fees and non-financial support from Boston Scientific, non-financial support from Medtronic, and personal fees from Edwards outside of the submitted work. Won-Keun Kim is a proctor/speaker/advisory board member to Abbott, Boston, Edwards, Med-tronic, Meril, and Shockwave. Dinos Verouhis reports grants from Boston Scientific during the conduct of the study. Nawzad Saleh reports grants from Boston Scientific during the conduct of the study, and grants, personal fees, and non-financial support from Boston Scientific outside of the submitted work. Darren Mylotte is a consultant for Medtronic, Boston Scientific, and Microport. Patrick Serruys reports personal fees from SMT, Philips/Volcano, Xeltis, Novartis and Merillife. Osama Soliman is Science Foundation of Ireland Funded investigator, and he reports several institutional research grants outside of the submitted work. All other authors declare no conflict of interest.
Funding Information:
Funding: This research received funding from Science Foundation of Ireland (SFI) via CÚRAM.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - The new-generation ACURATE neo2 system was commercially released in September 2020. In this study, we sought to compare the aortic regurgitation (AR) severity of the ACURATE neo2 versus the ACURATE neo transcatheter heart valve, using quantitative videodensitometric angiography (qAR). This is a retrospective, Corelab analysis of final post-transcatheter aortic valve implantation (TAVI) aortograms of patients treated with the ACURATE neo2 and ACURATE neo systems. The ACURATE neo2 cohort comprised consecutive patients treated between September 2020 and January 2021 at two centers. The ACURATE neo cohort included consecutive patients treated before September 2020. Our primary objective was to compare AR severity on qAR following TAVI with ACURATE neo2 and ACURATE neo. Out of 401 aortograms, 228 (56.9%) were ana-lyzable, with 120 in the ACURATE neo2 cohort, and 108 in the ACURATE neo cohort. The mean AR fraction was 4.4 ± 4.8% in the neo2 cohort, and 9.9 ± 8.2% in the neo cohort (p < 0.001). Furthermore, moderate or severe AR (qAR > 17%) was detected in 2 aortograms (1.7%) in the neo2 cohort and 15 aortograms (13.9%) in the neo cohort (p < 0.001). Quantitative aortography shows a lower rate of moderate or severe paravalvular AR in what is the first European experience of the new-generation, self-expanding ACURATE neo2 when compared to the first-generation ACURATE neo. Moreover, aortographic data need to be correlated and compared to Core Laboratory-adjudicated 30-day echo-cardiographic data.
AB - The new-generation ACURATE neo2 system was commercially released in September 2020. In this study, we sought to compare the aortic regurgitation (AR) severity of the ACURATE neo2 versus the ACURATE neo transcatheter heart valve, using quantitative videodensitometric angiography (qAR). This is a retrospective, Corelab analysis of final post-transcatheter aortic valve implantation (TAVI) aortograms of patients treated with the ACURATE neo2 and ACURATE neo systems. The ACURATE neo2 cohort comprised consecutive patients treated between September 2020 and January 2021 at two centers. The ACURATE neo cohort included consecutive patients treated before September 2020. Our primary objective was to compare AR severity on qAR following TAVI with ACURATE neo2 and ACURATE neo. Out of 401 aortograms, 228 (56.9%) were ana-lyzable, with 120 in the ACURATE neo2 cohort, and 108 in the ACURATE neo cohort. The mean AR fraction was 4.4 ± 4.8% in the neo2 cohort, and 9.9 ± 8.2% in the neo cohort (p < 0.001). Furthermore, moderate or severe AR (qAR > 17%) was detected in 2 aortograms (1.7%) in the neo2 cohort and 15 aortograms (13.9%) in the neo cohort (p < 0.001). Quantitative aortography shows a lower rate of moderate or severe paravalvular AR in what is the first European experience of the new-generation, self-expanding ACURATE neo2 when compared to the first-generation ACURATE neo. Moreover, aortographic data need to be correlated and compared to Core Laboratory-adjudicated 30-day echo-cardiographic data.
KW - ACURATE neo
KW - Aortic regurgitation
KW - Transcatheter aortic valve implantation
KW - Transcatheter heart valve
KW - Videodensitometry
UR - https://www.scopus.com/pages/publications/85116706631
U2 - 10.3390/jcm10204627
DO - 10.3390/jcm10204627
M3 - Article
C2 - 34682750
SN - 2077-0383
VL - 10
JO - Journal of clinical medicine
JF - Journal of clinical medicine
IS - 20
M1 - 4627
ER -